Trial: 202005167

A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

Phase

I/II

Principal Investigator

Oh, Stephen

Disease Site

Myeloproliferative Disease; Other Hematopoietic

Learn more about this study at: clinicaltrials.gov